Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQP1351 in Chinese CML-CP Patients with T315I Mutation
NCT03883087Phase 2Unknown
- Sponsor
- Ascentage Pharma
- Start
- Apr 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in chronic myeloid leukemia (CML), sponsored by Ascentage Pharma. Status: unknown.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03883087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883087.